OTCMKTS:NGENF NervGen Pharma (NGENF) Stock Price, News & Analysis → Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad) Free NGENF Stock Alerts $1.53 +0.03 (+2.27%) (As of 05/10/2024 08:56 PM ET) Add Compare Share Share Today's Range$1.49▼$1.5450-Day Range$1.43▼$2.4352-Week Range$1.15▼$2.99Volume35,000 shsAverage Volume67,798 shsMarket Capitalization$94.51 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest Get NervGen Pharma alerts: Email Address Ad Crypto 101 MediaThe Crypto 9-5 Escape PlanA brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guide About NervGen Pharma Stock (OTCMKTS:NGENF)NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. It has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.Read More NGENF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NGENF Stock News HeadlinesApril 20, 2024 | finance.yahoo.comNervGen Pharma Corp. (NGENF)April 17, 2024 | finance.yahoo.comNervGen Pharma Reports 2023 Year-End Financial Results and Operational UpdatesMay 13, 2024 | Unstoppable Prosperity (Ad)Charles Payne Demystifies OptionsWhen it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. March 28, 2024 | finance.yahoo.comNervGen Completes $23 Million Bought Deal FinancingMarch 22, 2024 | finance.yahoo.comCanadian Investment Regulatory Organization Trade Resumption - NGENMarch 21, 2024 | finance.yahoo.comNERVGEN ANNOUNCES $20 MILLION BOUGHT DEAL OFFERINGFebruary 15, 2024 | finance.yahoo.comNervGen Pharma on Track to Complete Enrollment, Deliver Data Readout in Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord InjuryNovember 9, 2023 | msn.comNervGen Pharma GAAP EPS of -$0.07May 13, 2024 | Unstoppable Prosperity (Ad)Charles Payne Demystifies OptionsWhen it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. November 8, 2023 | finance.yahoo.comNeuroscientist and NervGen Pharma Scientific Founder, Dr. Jerry Silver, Interviewed on 'Remarkable People' Podcast Hosted by Tech Luminary Guy KawasakiNovember 4, 2023 | morningstar.comNervGen Pharma Corp Ordinary Shares NGENFSeptember 25, 2023 | finance.yahoo.comNervGen Pharma Announces First Subject Dosed in Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord InjurySeptember 11, 2023 | finance.yahoo.comNervGen Pharma to Present at 2023 International Spinal Research Trust Network MeetingSeptember 5, 2023 | finance.yahoo.comNervGen Pharma to Present on Its Drug Candidate NVG-291 and Spinal Cord Injury at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 22, 2023 | finance.yahoo.comNervGen Pharma to Present on its Drug Candidate NVG-291 and Spinal Cord Injury at Investor ConferenceAugust 8, 2023 | finance.yahoo.comNervGen Pharma to Proceed with Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury Having Completed FDA Review and Received IRB ApprovalJune 27, 2023 | finance.yahoo.comNervGen Pharma to Receive More than US$3 Million from Wings for Life to Support Upcoming Clinical Study in Spinal Cord InjuryJune 20, 2023 | finance.yahoo.comNervGen Pharma to Present at Upcoming Investor ConferencesMay 15, 2023 | finanznachrichten.deNervGen Pharma Corp.: NervGen Pharma Reports Q1 2023 Results and Provides Operational Update Including Clinical Trials of Proprietary NVG-291May 15, 2023 | finance.yahoo.comNervGen Pharma Reports Q1 2023 Results and Provides Operational Update Including Clinical Trials of Proprietary NVG-291April 14, 2023 | bizjournals.comRaleigh/Durham Pharmaceuticals NewsApril 10, 2023 | finance.yahoo.comNervGen Pharma Appoints Michael Kelly as President & Chief Executive OfficerMarch 30, 2023 | finance.yahoo.comNervGen Pharma Reports 2022 Year End Results and Provides Operational Update Including Plans to Initiate Phase 1b/2a Clinical Trial of Proprietary NVG-291 in Q3 2023March 22, 2023 | ca.finance.yahoo.comNervGen Pharma Corp. (NGEN.V)February 14, 2023 | finance.yahoo.comNervGen Pharma Announces Completion of Dosing of All Subjects in Phase 1 Clinical Trial of Proprietary Drug Candidate NVG-291January 31, 2023 | seekingalpha.comNGEN:CA NervGen Pharma Corp.January 10, 2023 | benzinga.comNervGen Pharma Stock (OTC:NGENF), Quotes and News SummarySee More Headlines Receive NGENF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NervGen Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:NGENF CUSIPN/A CIKN/A WebN/A Phone(778) 731-1711FaxN/AEmployees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,070,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-73.14% Return on Assets-56.59% Debt Debt-to-Equity Ratio0.04 Current Ratio11.21 Quick Ratio11.21 Sales & Book Value Annual Sales$150,000.00 Price / Sales630.05 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares61,770,000Free FloatN/AMarket Cap$94.51 million OptionableNot Optionable BetaN/A 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. William Joseph Radvak BASc (Age 61)Co-Founder & Chairman Comp: $165.59kDr. Harold Martin Punnett D.M.D.Co-Founder & Independent DirectorMr. William J. Adams C.A. (Age 62)CPA, CA, CPA, CFO & Corporate Secretary Comp: $276.27kDr. Daniel D. Mikol M.D.Ph.D., Chief Medical OfficerMr. Michael Kelly (Age 58)CEO, President & Director Mr. Brian McAlisterCo-Founder & AdvisorMore ExecutivesKey CompetitorsAmpliphi BiosciencesNYSEAMERICAN:APHBBiopharmxNYSEAMERICAN:BPMXLianBioNASDAQ:LIANCybinOTCMKTS:CYBNMilestone PharmaceuticalsNASDAQ:MISTView All Competitors NGENF Stock Analysis - Frequently Asked Questions How have NGENF shares performed in 2024? NervGen Pharma's stock was trading at $2.04 at the beginning of the year. Since then, NGENF shares have decreased by 25.0% and is now trading at $1.53. View the best growth stocks for 2024 here. Are investors shorting NervGen Pharma? NervGen Pharma saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 276,400 shares, an increase of 301.2% from the April 15th total of 68,900 shares. Based on an average trading volume of 95,200 shares, the days-to-cover ratio is currently 2.9 days. View NervGen Pharma's Short Interest. How do I buy shares of NervGen Pharma? Shares of NGENF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:NGENF) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersBill Clinton Backing Biden Replacement???The Freeport SocietyThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe Crypto 9-5 Escape PlanCrypto 101 MediaProtect Your Bank Account Before It’s Too LateWeiss RatingsCharles Payne Demystifies OptionsUnstoppable ProsperityElon’s New Device is About to Shock the WorldInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NervGen Pharma Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
